Shares of Kura Oncology Inc (NASDAQ:KURA) have earned a consensus recommendation of “Buy” from the nine analysts that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price among analysts that have covered the stock in the last year is $27.00.
KURA has been the subject of several research reports. ValuEngine cut shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 24th. HC Wainwright set a $31.00 price target on shares of Kura Oncology and gave the stock a “buy” rating in a research report on Wednesday, May 8th. Zacks Investment Research raised shares of Kura Oncology from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Wednesday, May 8th. Oppenheimer reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Tuesday, March 19th. Finally, Citigroup upped their price target on shares of Kura Oncology from $18.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday.
Kura Oncology stock traded up $1.03 during trading hours on Friday, hitting $16.84. The company had a trading volume of 22,498 shares, compared to its average volume of 196,996. The stock has a market cap of $606.08 million, a price-to-earnings ratio of -9.79 and a beta of 2.79. The company has a debt-to-equity ratio of 0.05, a current ratio of 13.80 and a quick ratio of 13.80. Kura Oncology has a 1 year low of $10.20 and a 1 year high of $22.00.
Several institutional investors and hedge funds have recently made changes to their positions in KURA. Great Point Partners LLC lifted its position in shares of Kura Oncology by 30.7% in the 4th quarter. Great Point Partners LLC now owns 2,769,527 shares of the company’s stock worth $38,884,000 after purchasing an additional 650,421 shares during the period. Goldman Sachs Group Inc. lifted its position in shares of Kura Oncology by 3,082.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 641,231 shares of the company’s stock worth $10,638,000 after purchasing an additional 621,082 shares during the period. Dimensional Fund Advisors LP lifted its position in shares of Kura Oncology by 147.1% in the 1st quarter. Dimensional Fund Advisors LP now owns 390,993 shares of the company’s stock worth $6,486,000 after purchasing an additional 232,733 shares during the period. Fosun International Ltd purchased a new stake in shares of Kura Oncology in the 4th quarter worth approximately $2,643,000. Finally, Victory Capital Management Inc. lifted its position in shares of Kura Oncology by 10.1% in the 4th quarter. Victory Capital Management Inc. now owns 1,692,220 shares of the company’s stock worth $23,759,000 after purchasing an additional 155,910 shares during the period. 83.95% of the stock is owned by hedge funds and other institutional investors.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: Stock Symbol
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.